Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the combination of VELCADE and rituximab
improves progression free survival relative to rituximab alone in patients with relapsed or
refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have
previously responded to rituximab. This is an international study being conducted in the
United States and in many countries around the world. A complete list of study locations is
listed below.
Phase:
Phase 3
Details
Lead Sponsor:
Millennium Pharmaceuticals, Inc.
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.